Curated Literature
All 25 papers curated into MCA, ordered by year of publication. Each entry links to the original record on PubMed.
We thank the authors and research teams whose published work forms the evidence base of the Microbial Clinical Atlas. MCA is a derivative resource — every clinical claim ultimately rests on the primary studies cited below.
2026
Clostridioides difficile pathogenesis and control.
Clostridioides difficile infection in pediatric inflammatory bowel disease: current understanding and clinical challenges.
Antibiotic use and gut microbiome composition links from individual-level prescription data of 14,979 individuals.
2025
Bloodstream infection by Lactobacillus rhamnosus in a haematology patient: why metagenomics can make the difference.
2024
Microbiota-Based Therapeutics as New Standard-of-Care Treatment for Recurrent Clostridioides difficile Infection.
A Comparison of Currently Available and Investigational Fecal Microbiota Transplant Products for Recurrent Clostridioides difficile Infection.
Oral Pathobiont-Derived Outer Membrane Vesicles in the Oral–Gut Axis.
2023
Dysbiosis of a microbiota–immune metasystem in critical illness is associated with nosocomial infections.
2022
Within-host evolution of a gut pathobiont facilitates liver translocation.
2021
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.
Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice.
Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients.
The microbiome and human cancer.
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.
2020
Microbiota Insights in Clostridium difficile Infection and Inflammatory Bowel Disease.
The Intermucosal Connection between the Mouth and Gut in Commensal Pathobiont-Driven Colitis.
2019
First bloodstream infection caused by Prevotella copri in a heart failure elderly patient with Prevotella-dominated gut microbiota: a case report.
2018
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.
c-Maf-dependent regulatory T cells mediate immunological tolerance to a gut pathobiont.
Clonal Emergence of Invasive Multidrug-Resistant Staphylococcus epidermidis Deconvoluted via a Combination of Whole-Genome Sequencing and Microbiome Analyses.
Translocation of a gut pathobiont drives autoimmunity in mice and humans.
2015
Gastrointestinal Dissemination and Transmission of Staphylococcus aureus following Bacteremia.
2014
Role of the Intestinal Microbiota in Resistance to Colonization by Clostridium difficile.